Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%
Clinical trial NCT03808480 · UNKNOWN
Trial details
- NCT number
- NCT03808480
- Sponsor
- National Cancer Center, Korea
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-23
- Primary completion
- 2022-05-31
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.